ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Enzyme Targets Continued

July 19, 2010 | APPEARED IN VOLUME 88, ISSUE 29

I read with interest Mike Renier’s letter to the editor on pyruvate kinase (C&EN, May 17, page 5).

I’m a biochemist, and I have wondered why NAD kinase (only enzyme to produce NADP) has not been targeted for cancer therapy. This approach might be more effective than other kinase inhibitors such as pyruvate kinase.

The pharmaceutical companies have a library of kinase inhibitors. They might want to include NAD kinase inhibitors in their lists.

Jim Butler
Tucson

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment